Thomas L. LaPorte - Concepedia

Author

Thomas L. LaPorte

Bristol-Myers Squibb (United States)

Also Known As

Laporte, Thomas, T L LaPorte, T. L. LaPorte, Thomas L LaPorte, Thomas L. LaPorte, Thomas LaPorte, Thomas Laporte

Publications

556

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)The Bristol-Myers Squibb Children's Hospital

About

Thomas L. LaPorte is an author at Bristol-Myers Squibb (United States) specializing in pharmacology, engineering, and organic chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Engineering	7	7	362
2	Medicine	5	5	95
3	Natural Sciences	5	5	163
4	Biochemistry	5	5	156
5	Social Sciences	1	1	151

Thomas L. LaPorte

Publications

491

Citations

H-Index

Page 1

	Year	Citations
Pharmaceutical Roundtable Study Demonstrates the Value of Continuous Manufacturing in the Design of Greener Processes Peter Poechlauer, Juan Colberg, Elizabeth Fisher, Organic Process Research & Development EngineeringGreen ChemistryGreenness AssessmentProcess DevelopmentSocial Sciences	2013	151
Synthesis of allysine ethylene acetal using phenylalanine dehydrogenase from Thermoactinomyces intermedius Ronald L. Hanson, J. M. Howell, Thomas L. LaPorte, Enzyme and Microbial Technology Thermoactinomyces IntermediusBiosynthesisEngineeringBiochemistryPhenylalanine Dehydrogenase	2000	73
Development and Scale-Up of Three Consecutive Continuous Reactions for Production of 6-Hydroxybuspirone Thomas L. LaPorte, Mourad Hamedi, Jeffrey S. DePue, Organic Process Research & Development Scalable EnolizationChemical EngineeringFlow ChemistryEngineeringProcess Intensification	2008	58
Synthesis and activity of a C-8 keto pleuromutilin derivative Dane M. Springer, Margaret E. Sorenson, Stella Huang, Bioorganic & Medicinal Chemistry Letters Natural Product SynthesisPharmaceutical ChemistryBiomolecular EngineeringC-8 Keto Pleuromutilin	2003	37
Continuous processes for the production of pharmaceutical intermediates and active pharmaceutical ingredients. Thomas L. LaPorte, Chenchi Wang PubMed EngineeringProcess DevelopmentOrganic ChemistryChemistryPharmaceutical Formulation	2007	35
Biocatalytic preparation of a chiral synthon for a vasopeptidase inhibitor: enzymatic conversion of N2-[N-Phenylmethoxy)carbonyl] L-homocysteinyl]- L-lysine (1- > 1′)-disulfide to [4S-(4I,7I,10aJ)] 1-octahydro-5-oxo-4-[phenylmethoxy)carbonyl]amino]-7H-pyrido-[2,1-b] [1,3]thiazepine-7-carboxylic acid methyl ester by a novel L-lysine ϵ-aminotransferase Ramesh N. Patel, Amit Banerjee, Venkata Nanduri, Enzyme and Microbial Technology Medicinal ChemistryPharmaceutical ChemistryBiocatalytic PreparationBiochemistryNatural Sciences	2000	33
Development of a Continuous Plug Flow Process for Preparation of a Key Intermediate for Brivanib Alaninate Thomas L. LaPorte, Lori A. Spangler, Mourad Hamedi, Organic Process Research & Development	2014	23
Biochemical approaches to the synthesis of ethyl 5-(s)-hydroxyhexanoate and 5-(s)-hydroxyhexanenitrile Venkata Nanduri, Ronald L. Hanson, Animesh Goswami, Enzyme and Microbial Technology BiosynthesisBioorganic ChemistryEngineeringBiochemistryNatural Sciences	2001	21
Commercial Synthesis of a Pyrrolotriazine–Fluoroindole Intermediate to Brivanib Alaninate: Process Development Directed toward Impurity Control Jaan A. Pesti, Thomas L. LaPorte, John E. Thornton, Organic Process Research & Development Organic ChemistryFluoroindole IntermediatePharmacotherapyChemistryPharmaceutical Chemistry	2013	21
The Effect of Additives on the Zinc Carbenoid-Mediated Cyclopropanation of a Dihydropyrrole Antonio Ramı́rez, Vu Chi Truc, Michael J. Lawler, The Journal of Organic Chemistry Induction PeriodMedicinal ChemistryDerivativesHeterocyclicBiochemistry	2014	15

Page 1